

Type	Session Name	Presentation No.	Submission No.	Title	First Name	Family Name	Country/District	Day	Session Start	Start of each	End of each	Min.	Place
Oral	Free Paper Session 1	FPS1-1	10053	Implementing Community-Based Hepatitis B Screening and Hepatocellular Carcinoma Screening in Resource-Limited Settings: A Qualitative Evaluation of Thailand's EZ Liver Network	Passakorn	Wanchajiraboon	Thailand	April 2 (Day 1)	9:10	9:10	9:18	8min.	Room 2
Oral	Free Paper Session 1	FPS1-2	10223	A Large-Center Comparison of Hepatocellular Carcinoma Characteristics in Hepatitis C Patients Treated With Direct-Acting Antivirals Versus Untreated Patients	Mohamed	Abdel-Samee	Egypt	April 2 (Day 1)	9:10	9:18	9:26	8min.	Room 2
Oral	Free Paper Session 1	FPS1-3	10107	Reduced Performance of Alpha-fetoprotein in Sustained Virological Response-related and Non-viral Early Hepatocellular Carcinoma: Complementary Value of PIVKA-II	Yuji	Ikeda	Japan	April 2 (Day 1)	9:10	9:26	9:34	8min.	Room 2
Oral	Free Paper Session 1	FPS1-4	10131	Clinical Characteristics and Surveillance Impact on Non-Viral Hepatocellular Carcinoma: A 20-Year Observational Study	Katsuya	Nagaoka	Japan	April 2 (Day 1)	9:10	9:34	9:42	8min.	Room 2
Oral	Free Paper Session 1	FPS1-5	10118	Integrative Clinical and Molecular Risk Score for Prevention of HBV-related HCC	Hiroyuki	Suzuki	USA	April 2 (Day 1)	9:10	9:42	9:50	8min.	Room 2
Oral	Free Paper Session 1	FPS1-6	10120	Serum Biomarker-based Score to Evaluate HCC Risk in HCV-cured Patients	Hiroaki	Kanzaki	USA	April 2 (Day 1)	9:10	9:50	9:58	8min.	Room 2
Oral	Free Paper Session 2	FPS2-1	10123	Hepatocellular Carcinoma Stage, Treatment Patterns, and Survival Outcomes in a Contemporary Multicentre International Cohort	Yin Min	Hwang	Singapore	April 2 (Day 1)	10:00	10:00	10:08	8min.	Room 2
Oral	Free Paper Session 2	FPS2-2	10091	Development and Validation of a Deep Learning Model to Prognosticate Hepatocellular Carcinoma	Juequn	Zhou	Singapore	April 2 (Day 1)	10:00	10:08	10:16	8min.	Room 2
Oral	Free Paper Session 2	FPS2-3	10122	Young Onset Hepatocellular Carcinoma Presents at Advanced Stage with Limited Treatment Options	Amruthavarshini	Nagabhushana	India	April 2 (Day 1)	10:00	10:16	10:24	8min.	Room 2
Oral	Free Paper Session 2	FPS2-4	10136	Environmental Exposure to Cadmium, Lead, and Mercury as a Public Health Risk Factor for Hepatocellular Carcinoma	Ankush	Kumar	India	April 2 (Day 1)	10:00	10:24	10:32	8min.	Room 2
Oral	Free Paper Session 2	FPS2-5	10151	Feasibility and Safety of Hepatic Rehabilitation in HCC Patients with Decompensated Cirrhosis	Takumi	Kawaguchi	Japan	April 2 (Day 1)	10:00	10:32	10:40	8min.	Room 2
Oral	Free Paper Session 3	FPS3-1	10011	Aging-Driven Immunosuppressive Remodeling of the Tumor Microenvironment in Gallbladder Cancer: Insights from Single-Cell Transcriptomics	Lei	Kong	China	April 2 (Day 1)	11:00	11:00	11:08	8min.	Room 2
Oral	Free Paper Session 3	FPS3-2	10144	KLF5 Mediates a Galectin1-FBP1-RAS/ERK Cascade to Drive Proliferation and Migration in Intrahepatic Cholangiocarcinoma	Xing	Yu	China	April 2 (Day 1)	11:00	11:08	11:16	8min.	Room 2
Oral	Free Paper Session 3	FPS3-3	10167	Lactylation of PPP1CA at K305 Promotes Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma by Sustaining TGF-β; Signaling	Yuheng	Hu	China	April 2 (Day 1)	11:00	11:16	11:24	8min.	Room 2
Oral	Free Paper Session 3	FPS3-4	10202	Epigenetic Silencing of PTEN as a Prognostic and Translational Biomarker in Periapillary Adenocarcinoma	Asgar	Ali	India	April 2 (Day 1)	11:00	11:24	11:32	8min.	Room 2
Oral	Free Paper Session 3	FPS3-5	10184	Prognostic impact of adipose tissue volume in unresectable biliary tract cancer treated with gemcitabine, cisplatin, and immunotherapy	Tsuyoshi	Takeda	Japan	April 2 (Day 1)	11:00	11:32	11:40	8min.	Room 2
Oral	Free Paper Session 3	FPS3-6	10172	Feasibility and Safety of Endoscopic Ultrasound-guided Tissue Acquisition for Biliary Lesions	Keito	Nakagawa	Japan	April 2 (Day 1)	11:00	11:40	11:48	8min.	Room 2
Oral	Late Breaker Session 1	LBS1-1	10248	HLA-DR⁺/⁺ Tumor Cells Mimic Antigen-presenting Cells to Mediate Immunosuppression in HBV-related Hepatocellular Carcinoma	Wenjing	Yuan	China	April 2 (Day 1)	13:30	13:30	13:38	8min.	Room 2
Oral	Late Breaker Session 1	LBS1-2	10236	High Ammonia Promotes EHHADH-dependent Pyrimidine Degradation to Induce Inflammatory Cell Death in HCC	Jinhui	Wei	China	April 2 (Day 1)	13:30	13:38	13:46	8min.	Room 2
Oral	Late Breaker Session 1	LBS1-3	10239	Sarcomatoid Transformation is Associated with Immunosuppressive Remodeling in Hepatocellular Carcinoma	Ryo	Morise	Japan	April 2 (Day 1)	13:30	13:46	13:54	8min.	Room 2
Oral	Late Breaker Session 1	LBS1-4	10254	Bile-based Liquid Biopsy for Diagnosis and Therapeutic Stratification of Biliary Strictures	Hiroshi	Ohyama	Japan	April 2 (Day 1)	13:30	13:54	14:02	8min.	Room 2
Oral	Late Breaker Session 2	LBS2-1	10246	Large Language Models Underperform Multidisciplinary Teams for Hepatocellular Carcinoma Treatment Decisions Despite Escalating Prompting Strategies: A Prospective Study	Amith	Vishwanath	India	April 2 (Day 1)	14:02	14:02	14:10	8min.	Room 2
Oral	Late Breaker Session 2	LBS2-2	10272	Causal Machine Learning-Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma	Jun-Hao	Mei	China	April 2 (Day 1)	14:02	14:10	14:18	8min.	Room 2
Oral	Late Breaker Session 2	LBS2-3	10232	NEO-ERA-01: A phase II Study of Neoadjuvant HAIC (GEMOX) Plus Adebrelimab and Lenvatinib in High-risk Resectable Intrahepatic Cholangiocarcinoma	Jianhua	Rao	China	April 2 (Day 1)	14:02	14:18	14:26	8min.	Room 2
Oral	Late Breaker Session 2	LBS2-4	10250	Stage-dependent Liver Stiffness Resolution after HCV SVR: a Longitudinal 8-year Follow-up Study	Shuntaro	Obi	Japan	April 2 (Day 1)	14:02	14:26	14:34	8min.	Room 2
Oral	Late Breaker Session 3	LBS3-1	10241	Efficacy and Safety of Postoperative Adjuvant Donafenib Therapy in Patients with High-risk Recurrence after Radical Resection of Hepatocellular Carcinoma: A Multicenter Retrospective Study	Jianhua	Rao	China	April 2 (Day 1)	14:50	14:50	14:58	8min.	Room 2
Oral	Late Breaker Session 3	LBS3-2	10273	The Risk of Decompensation in Steatotic Liver Disease-related Hepatocellular Carcinoma after Curative Treatment	Yuki	Matsushita	Japan	April 2 (Day 1)	14:50	14:58	15:06	8min.	Room 2
Oral	Free Paper Session 4	FPS4-1	10094	MicroRNA-199a-5p Disrupts Unfolded Protein Response-mediated Stress Adaptation in Hepatocellular Carcinoma Cells	Chaiyaboot	Ariyachet	Thailand	April 2 (Day 1)	15:10	15:10	15:18	8min.	Room 2
Oral	Free Paper Session 4	FPS4-2	10108	Dynamic Regulation of Membrane Fluidity Drives Tumor Evolution and Attenuates TNF α-Mediated Apoptosis in Hepatocellular Carcinoma	Boqiang	Liu	China	April 2 (Day 1)	15:10	15:18	15:26	8min.	Room 2
Oral	Free Paper Session 4	FPS4-3	10162	AARS1 Promotes Tumor Progression and Immune Evasion through ATF6 Lactylation-driven Tryptophan Metabolism in Hepatocellular Carcinoma	Yiming	Wang	China	April 2 (Day 1)	15:10	15:26	15:34	8min.	Room 2
Oral	Free Paper Session 4	FPS4-4	10178	Dna5-dependent Hepatocyte Death Promotes Inflammatory TNF Signaling in Kupffer Cells to Drive Hepatocarcinogenesis	Tomoya	Hamabe	Japan	April 2 (Day 1)	15:10	15:34	15:42	8min.	Room 2
Oral	Free Paper Session 5	FPS5-1	10100	Natural Killer Cell Drives Liver Cancer Evolution Through Cholesterol Metabolism Reprogramming	Liang	Shi	China	April 2 (Day 1)	15:45	15:45	15:53	8min.	Room 2
Oral	Free Paper Session 5	FPS5-2	10147	A Fe-Curcumin-based Strategy to Reinvigorate CAR-T Cells by Reversing Exhaustion and Senescence in Liver Cancer	Yuchan	Xue	China	April 2 (Day 1)	15:45	15:53	16:01	8min.	Room 2
Oral	Free Paper Session 5	FPS5-3	10119	Reverse-engineering Strategy Identified DDR1 as HCC Chemoprevention Target Post HCV Cure	Hiroaki	Kanzaki	USA	April 2 (Day 1)	15:45	16:01	16:09	8min.	Room 2
Oral	Plenary Session	PS-1	10177	Plasma TWEAK as a Predictive Biomarker of Response to Tremelimumab plus Durvalumab in Advanced Hepatocellular Carcinoma	Takeru	Hirao	Japan	April 3 (Day 2)	16:05	16:05	16:15	10min.	Room 1
Oral	Plenary Session	PS-2	10130	Surgical Benefit and Futility in Borderline Resectable Hepatocellular Carcinoma: A Multicenter Study	Norifumi	Iseda	Japan	April 3 (Day 2)	16:05	16:15	16:25	10min.	Room 1
Oral	Plenary Session	PS-3	10003	The First Application and Feasibility Assessment of 5G-enabled Remote Robot-assisted Hepatobiliary and Pancreatic Surgery in Patients with Malignant Tumors	Xingru	Wang	China	April 3 (Day 2)	16:05	16:25	16:35	10min.	Room 1
Video	Video Session	VS-1	10073	Pitfalls in Posterior Sectionectomy and S7 Segmentectomy Focusing on the Running Pattern of the Right Posterior Inferior Portal Branch (P6a) and Portal Vein Branching Anatomy	Gakushi	Kitamura	Japan	April 3 (Day 2)	9:00	9:00	9:12	12min.	Room 2
Video	Video Session	VS-2	10074	Surgical Strategy for Laparoscopic Right Intersectional Plane Resection in Right Anterior/Posterior Sectionectomy and S7/S8 Segmentectomy, Based on the Courses of P6a and the Right Hepatic Vein	Yusuke	Yamamoto	Japan	April 3 (Day 2)	9:00	9:12	9:24	12min.	Room 2
Video	Video Session	VS-3	10004	Infrared Laser-guided Laparoscopic Portal Vein Drainage Area Anatomic Liver Resection Using ICG Positive Staining	Xingru	Wang	China	April 3 (Day 2)	9:00	9:24	9:36	12min.	Room 2
Video	Video Session	VS-4	10077	Optimizing Specimen Extraction in Laparoscopic Resection of Giant Liver Tumors Using a Pfannenstiel Incision	Rie	Shibata	Japan	April 3 (Day 2)	9:00	9:36	9:48	12min.	Room 2
Video	Video Session	VS-5	10143	Advanced Minimally Invasive Hepatectomy Through Standardized Hepatic Vein Control- Translating Laparoscopic Strategies to Robotic Surgery -	Taisuke	Imamura	Japan	April 3 (Day 2)	9:00	9:48	10:00	12min.	Room 2
Video	Video Session	VS-6	10069	Initial Experience with Robot-assisted Liver Resection Using the da Vinci SP System	Mei	Nakamura	Japan	April 3 (Day 2)	9:00	10:00	10:12	12min.	Room 2
Video	Video Session	VS-7	10090	EUS-Guided Portal Vein Sampling as a Novel Liquid Biopsy Approach for Pancreatic Cancer	Hiroki	Yamana	Japan	April 3 (Day 2)	9:00	10:12	10:24	12min.	Room 2
Oral	Free Paper Session 6	FPS6-1	10038	Clinical Characteristics of Combination Immunotherapy in Elderly Patients with Unresectable Hepatocellular Carcinoma	Chikako	Nagao	Japan	April 3 (Day 2)	10:45	10:45	10:53	8min.	Room 2
Oral	Free Paper Session 6	FPS6-2	10064	Prognostic Value of Combined Child–Pugh Score and Modified Albumin–Bilirubin Grade in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab	Tomonao	Taira	Japan	April 3 (Day 2)	10:45	10:53	11:01	8min.	Room 2
Oral	Free Paper Session 6	FPS6-3	10106	Association of Lenvatinib Pharmacokinetics with mALBI in Hepatocellular Carcinoma and Evaluation of Efficacy and Safety	Yumi	Otoyama	Japan	April 3 (Day 2)	10:45	11:01	11:09	8min.	Room 2
Oral	Free Paper Session 6	FPS6-4	10139	Regional Lymph Node Metastasis in Hepatocellular Carcinoma Treated with Immune-based Systemic Therapy: Prognostic Significance and Implications for Clinical Staging	Qian	Chen	China	April 3 (Day 2)	10:45	11:09	11:17	8min.	Room 2
Oral	Free Paper Session 7	FPS7-1	10097	Should Transarterial Chemoembolization Be Applied with Systemic Therapy for Hepatocellular Carcinoma with Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus?: A Multicenter Study	Long-Wang	Lin	China	April 3 (Day 2)	11:17	11:17	11:25	8min.	Room 2
Oral	Free Paper Session 7	FPS7-2	10160	Real-World Outcomes of Sequential Transarterial Chemoembolization followed by Atezolizumab-Bevacizumab in Patients with Advanced Hepatocellular Carcinoma	Soe Thiha	Maung	Thailand	April 3 (Day 2)	11:17	11:25	11:33	8min.	Room 2
Oral	Free Paper Session 7	FPS7-3	10183	Efficacy of Combined Three-Dimensional Conformal Radiotherapy and Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion	Joji	Tani	Japan	April 3 (Day 2)	11:17	11:33	11:41	8min.	Room 2
Oral	Free Paper Session 8	FPS8-1	10111	Prognostic Impact of the Oncological Resectability Criteria in Patients Undergoing Liver Resection for Hepatocellular Carcinoma	Hayato	Abe	Japan	April 3 (Day 2)	13:30	13:30	13:38	8min.	Room 2
Oral	Free Paper Session 8	FPS8-2	10078	Surgical Outcomes and Treatment Strategies for Solitary Giant Hepatocellular Carcinoma	Atomu	Suzuki	Japan	April 3 (Day 2)	13:30	13:38	13:46	8min.	Room 2
Oral	Free Paper Session 8	FPS8-3	10146	Association between Prophylactic Antibiotics and Post-ablation Infections in Hepatocellular Carcinoma Patients: A Retrospective Multicenter Cohort Study	Ting	Luo	China	April 3 (Day 2)	13:30	13:46	13:54	8min.	Room 2
Oral	Free Paper Session 9	FPS9-1	10076	PIVKA-II Monitoring to Predict Response to the First Transarterial Chemoembolization (TACE) in Intermediate-Stage Hepatocellular Carcinoma	Chitchai	Rattananukrom	Thailand	April 3 (Day 2)	13:55	13:55	14:03	8min.	Room 2
Oral	Free Paper Session 9	FPS9-2	10158	Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Refractory Gastrointestinal Bleeding in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis: A Prospective Cohort Study	Atteyat	Semeya	Saudi Arabia	April 3 (Day 2)	13:55	14:03	14:11	8min.	Room 2
Oral	Free Paper Session 10	FPS10-1	10029	Development of Novel Deep Multimodal Representation Learning-based Model for the Differentiation of Liver Tumors on B-Mode Ultrasound Images	Masaya	Sato	Japan	April 3 (Day 2)	14:15	14:15	14:23	8min.	Room 2
Oral	Free Paper Session 10	FPS10-2	10204	Dissociation between Multiphasic CT-Defined Tumor Burden and Endoscopic Portal Hypertension Severity in Cirrhotic and Non-Cirrhotic Hepatocellular Carcinoma	Aldisa	Puspitasari	Indonesia	April 3 (Day 2)	14:15	14:23	14:31	8min.	Room 2
Oral	Free Paper Session 10	FPS10-3	10210	Stereotactic Body Radiotherapy Enhances the Efficacy of Nivolumab in Advanced Hepatocellular Carcinoma: A Comparative Cohort Analysis	Phool	Chand	India	April 3 (Day 2)	14:15	14:31	14:39	8min.	Room 2
Oral	Young Investigator Award Session 1	YIA1-1	10013	Repurposing Resmetromir Suppresses MASH-associated Hepatocellular Carcinoma, with Mechanistic Implications of MDK/LRP1-mediated Metabolic Reprogramming and Immunosuppression	Vanilla Xin	Zhang	Hong Kong	April 3 (Day 2)	15:00	15:00	15:08	8min.	Room 2
Oral	Young Investigator Award Session 1	YIA1-2	10017	Transitional Hepatocytes and Immunosuppressive Macrophages Drive NASH-Associated Liver Cancer Revealed by Single-Cell Transcriptomics	Firdian	Makrufardi	Indonesia	April 3 (Day 2)	15:00	15:08	15:16	8min.	Room 2
Oral	Young Investigator Award Session 1	YIA1-3	10047	Gemcitabine Modulates the Tumor Immune Microenvironment to Enhance Response to Immune-checkpoint Inhibitors in Biliary Tract Cancer	Kenji	Nose	Japan	April 3 (Day 2)	15:00	15:16	15:24	8min.	Room 2
Oral	Young Investigator Award Session 1	YIA1-4	10065	Strategic Integration of Locoregional Interventions to Optimize Survival Outcomes following First-line ICI Combinations in Advanced Hepatocellular Carcinoma	Masaki	Omori	Japan	April 3 (Day 2)	15:00	15:24	15:32	8min.	Room 2
Oral	Young Investigator Award Session 2	YIA2-1	10020	Impact of Antihypertensive Drug Selection on Proteinuria Risk During Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma	Takashi	Kitagataya	Japan	April 3 (Day 2)	15:32	15:32	15:40	8min.	Room 2
Oral	Young Investigator Award Session 2	YIA2-2	10060	Pretreatment Serum Heparin-Binding Protein as a Predictive Biomarker for Atezolizumab Plus Bevacizumab Therapy in Advanced Hepatocellular Carcinoma	Satoshi	Narahara	Japan	April 3 (Day 2)	15:32	15:40	15:48	8min.	Room 2
Oral	Young Investigator Award Session 2	YIA2-3	10041	Novel Risk Score Incorporating Type-IV Collagen, Albumin, and Prothrombin Time (CAP score) to Predict 180-Day Surgery-Related Mortality After Liver Resection for Hepatocellular Carcinoma	Tomoaki	Hayakawa	Japan	April 3 (Day 2)	15:32	15:48	15:56	8min.	Room 2
Oral	Young Investigator Award Session 2	YIA2-4	10070	Unexpected Rapid Progression of Hepatocellular Carcinoma After Radiofrequency Ablation	Takuma	Kaneko	Japan	April 3 (Day 2)	15:32	15:56	16:04	8min.	Room 2